Articles related to OBESITY/WEIGHT MANAGEMENT

Medicare’s new GLP-1 Bridge Program expands lower-cost access to certain weight-loss medications for eligible beneficiaries. Concurrent ISMP guidance outlines common medication errors and counseling challenges as more patients initiate GLP-1 therapy.

Nearly 89% of U.S. ischemic heart disease deaths in 2023 were attributable to modifiable risk factors, according to Global Burden of Disease data. Mortality rates declined substantially since 1990, although deaths linked to elevated BMI and fasting glucose increased.

A national analysis found that clinical obesity was present in more than one-quarter of adults with normal BMI values. The findings highlight limitations of BMI alone for identifying excess adiposity and obesity-related health risk.

A phase 2b trial found that biweekly bofanglutide significantly reduced HbA1c levels and produced weight loss in adults with type 2 diabetes. The findings add to ongoing development of longer-interval GLP-1 therapies, though larger and longer studies remain necessary.

Six weeks of moderate sleep restriction increased weight, waist circumference, and sedentary time in adults with baseline adequate sleep and elevated cardiometabolic risk.

The FDA has begun reviewing generic tirzepatide applications as global competition accelerates, despite US patent protections limiting near-term availability.